Found: 36
Select item for more details and to access through your institution.
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.755623
- By:
- Publication type:
- Article
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA).
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 1, p. 203, doi. 10.1111/bjh.18198
- By:
- Publication type:
- Article
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2021, v. 195, n. 3, p. 388, doi. 10.1111/bjh.17673
- By:
- Publication type:
- Article
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 690, doi. 10.1111/bjh.17527
- By:
- Publication type:
- Article
Prognostic utility of pre‐transplantation [<sup>18</sup>F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B‐cell lymphoma who underwent rituximab, dexamethasone, high‐dose cytarabine, carboplatin salvage chemotherapy
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 2, p. 268, doi. 10.1111/bjh.16144
- By:
- Publication type:
- Article
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 5, p. 755, doi. 10.1111/bjh.15641
- By:
- Publication type:
- Article
Hodgkin lymphoma: is there really a need for interim and end‐of‐treatment FDG‐PET evaluations? – Response to Adams & Kwee.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Hodgkin lymphoma: a negative interim- PET cannot circumvent the need for end-of-treatment- PET evaluation.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 4, p. 652, doi. 10.1111/bjh.14292
- By:
- Publication type:
- Article
Bendamustine is effective in T-Cell prolymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 6, p. 916, doi. 10.1111/bjh.13175
- By:
- Publication type:
- Article
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. 302, doi. 10.1002/ajh.26068
- By:
- Publication type:
- Article
Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 2, p. 317, doi. 10.1007/s00277-021-04689-4
- By:
- Publication type:
- Article
Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 2, p. 233, doi. 10.1007/s00277-013-1860-8
- By:
- Publication type:
- Article
Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level.
- Published in:
- Annals of Hematology, 2012, v. 91, n. 1, p. 39, doi. 10.1007/s00277-011-1242-z
- By:
- Publication type:
- Article
Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1761, doi. 10.3390/cancers14071761
- By:
- Publication type:
- Article
Clinical presentation, outcome, and prognostic markers in patients with intravascular large B‐cell lymphoma, a lymphoma study association (LYSA) retrospective study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 19, p. 3602, doi. 10.1002/cam4.4742
- By:
- Publication type:
- Article
90Y Ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2011, v. 11, n. 2, p. 212, doi. 10.1016/j.clml.2011.03.007
- By:
- Publication type:
- Article
Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained.
- Published in:
- 2017
- By:
- Publication type:
- Editorial
Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 3, p. 1, doi. 10.2967/jnumed.120.242594
- By:
- Publication type:
- Article
Early <sup>18</sup>F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.232827
- By:
- Publication type:
- Article
Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
- Published in:
- PLoS ONE, 2017, v. 12, n. 3, p. 1, doi. 10.1371/journal.pone.0172147
- By:
- Publication type:
- Article
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 1, p. 108, doi. 10.1002/hon.3089
- By:
- Publication type:
- Article
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 362, doi. 10.1002/ajh.25711
- By:
- Publication type:
- Article
Rétrospective de la prise en charge des lymphomes T : 10 ans de recul.
- Published in:
- Hematologie, 2020, p. 17, doi. 10.1684/hma.2020.1609
- By:
- Publication type:
- Article
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Response to the letter by Adams and Kwee, entitled: 'Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma'.
- Published in:
- 2017
- By:
- Publication type:
- Letter